Literature DB >> 19924795

Expression of interleukin 15 in primary adult acute lymphoblastic leukemia.

Shuling Wu1, Lars Fischer, Nicola Gökbuget, Stefan Schwartz, Thomas Burmeister, Michael Notter, Dieter Hoelzer, Hendrik Fuchs, Igor Wolfgang Blau, Wolf K Hofmann, Eckhard Thiel.   

Abstract

BACKGROUND: Interleukin-15 (IL-15) has been associated with the growth, survival and biological behavior of leukemic cells and response to therapy. We determined the expression of IL-15 in lymphoblasts and evaluated its potential impact on the outcome in adult acute lymphoblastic leukemia (ALL).
METHODS: Between June 1999 and June 2006, ALL samples were collected from 87 adult patients before initiation of antineoplastic therapy. These patients were enrolled in the German Multicenter Acute Lymphoblastic Leukemia June 1999 and July 2003 study trials. The expression of IL-15 in leukemic cells was analyzed by real-time polymerase chain reaction.
RESULTS: The expression of IL-15 correlated with the immunophenotype: T-lineage ALL had a more than 4-fold higher IL-15 mRNA expression as compared with B-cell precursor (BCP)-ALL (P < .001). Patients with BCR-ABL(+)-BCP-ALL had lower IL-15 expression compared with BCR-ABL(-)-BCP-ALL (P = .041). Furthermore, higher expression of IL-15 was associated with mediastinal (P = .001) and lymph node infiltration (P = .051), but not with hepatomegaly and splenomegaly. Notably, high IL-15 expression in BCP-ALL was associated with an inferior relapse-free survival (RFS) at 5 years (0.17 +/- 0.13 vs 0.47 +/- 0.13) (P = .008), but there was no impact on overall survival (P = .249).
CONCLUSIONS: Differential expression of IL-15 in adult ALL at diagnosis was associated with clinical features and outcome, in particular, RFS. It remains to be evaluated whether IL-15 might be a relevant therapy target, or might be used for risk stratification.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19924795     DOI: 10.1002/cncr.24729

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.

Authors:  Martin Felices; Todd R Lenvik; Behiye Kodal; Alexander J Lenvik; Peter Hinderlie; Laura E Bendzick; Dawn K Schirm; Michael F Kaminski; Ron T McElmurry; Melissa A Geller; Craig E Eckfeldt; Daniel A Vallera; Jeffrey S Miller
Journal:  Cancer Immunol Res       Date:  2020-07-13       Impact factor: 11.151

Review 2.  Interleukin-15 biology and its therapeutic implications in cancer.

Authors:  Jason C Steel; Thomas A Waldmann; John C Morris
Journal:  Trends Pharmacol Sci       Date:  2011-10-25       Impact factor: 14.819

3.  Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Authors:  Nimitha R Mathew; Francis Baumgartner; Lukas Braun; David O'Sullivan; Simone Thomas; Miguel Waterhouse; Tony A Müller; Kathrin Hanke; Sanaz Taromi; Petya Apostolova; Anna L Illert; Wolfgang Melchinger; Sandra Duquesne; Annette Schmitt-Graeff; Lena Osswald; Kai-Li Yan; Arnim Weber; Sonia Tugues; Sabine Spath; Dietmar Pfeifer; Marie Follo; Rainer Claus; Michael Lübbert; Christoph Rummelt; Hartmut Bertz; Ralph Wäsch; Johanna Haag; Andrea Schmidts; Michael Schultheiss; Dominik Bettinger; Robert Thimme; Evelyn Ullrich; Yakup Tanriver; Giang Lam Vuong; Renate Arnold; Philipp Hemmati; Dominik Wolf; Markus Ditschkowski; Cordula Jilg; Konrad Wilhelm; Christian Leiber; Sabine Gerull; Jörg Halter; Claudia Lengerke; Thomas Pabst; Thomas Schroeder; Guido Kobbe; Wolf Rösler; Soroush Doostkam; Stephan Meckel; Kathleen Stabla; Stephan K Metzelder; Sebastian Halbach; Tilman Brummer; Zehan Hu; Joern Dengjel; Björn Hackanson; Christoph Schmid; Udo Holtick; Christof Scheid; Alexandros Spyridonidis; Friedrich Stölzel; Rainer Ordemann; Lutz P Müller; Flore Sicre-de-Fontbrune; Gabriele Ihorst; Jürgen Kuball; Jan E Ehlert; Daniel Feger; Eva-Maria Wagner; Jean-Yves Cahn; Jacqueline Schnell; Florian Kuchenbauer; Donald Bunjes; Ronjon Chakraverty; Simon Richardson; Saar Gill; Nicolaus Kröger; Francis Ayuk; Luca Vago; Fabio Ciceri; Antonia M Müller; Takeshi Kondo; Takanori Teshima; Susan Klaeger; Bernhard Kuster; Dennis Dong Hwan Kim; Daniel Weisdorf; Walter van der Velden; Daniela Dörfel; Wolfgang Bethge; Inken Hilgendorf; Andreas Hochhaus; Geoffroy Andrieux; Melanie Börries; Hauke Busch; John Magenau; Pavan Reddy; Myriam Labopin; Joseph H Antin; Andrea S Henden; Geoffrey R Hill; Glen A Kennedy; Merav Bar; Anita Sarma; Donal McLornan; Ghulam Mufti; Betul Oran; Katayoun Rezvani; Omid Shah; Robert S Negrin; Arnon Nagler; Marco Prinz; Andreas Burchert; Andreas Neubauer; Dietrich Beelen; Andreas Mackensen; Nikolas von Bubnoff; Wolfgang Herr; Burkhard Becher; Gerard Socié; Michael A Caligiuri; Eliana Ruggiero; Chiara Bonini; Georg Häcker; Justus Duyster; Jürgen Finke; Erika Pearce; Bruce R Blazar; Robert Zeiser
Journal:  Nat Med       Date:  2018-02-12       Impact factor: 53.440

4.  Central nervous system acute lymphoblastic leukemia: role of natural killer cells.

Authors:  Liron Frishman-Levy; Avishai Shemesh; Allan Bar-Sinai; Chao Ma; Zhenya Ni; Shahar Frenkel; Vera Muench; Hilke Bruckmueller; Christian Vokuhl; Klaus-Michael Debatin; Cornelia Eckert; Martin Stanulla; Martin Schrappe; Kerry S Campbell; Ron Loewenthal; Denis M Schewe; Jacob Hochman; Lueder H Meyer; Dan Kaufman; Gunnar Cario; Angel Porgador; Shai Izraeli
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

5.  Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma.

Authors:  Hua Wang; Jia-Yu Zhu; Cheng-Cheng Liu; Meng-Yuan Zhu; Jing-Hua Wang; Qi-Rong Geng; Yue Lu
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

6.  The role of interleukin-15 polymorphisms in adult acute lymphoblastic leukemia.

Authors:  Dandan Lin; Chunliang Liu; Mengxing Xue; Rengyun Liu; Lan Jiang; Xiao Yu; Guangming Bao; Fang Deng; Mingjie Yu; Jiafu Ao; Yifeng Zhou; Depei Wu; Haiyan Liu
Journal:  PLoS One       Date:  2010-10-25       Impact factor: 3.240

7.  Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.

Authors:  Anjali Mishra; Krista La Perle; Sonya Kwiatkowski; Laura A Sullivan; Gregory H Sams; Jessica Johns; Douglas P Curphey; Jing Wen; Kathleen McConnell; Jun Qi; Henry Wong; Giandomenico Russo; Jianying Zhang; Guido Marcucci; James E Bradner; Pierluigi Porcu; Michael A Caligiuri
Journal:  Cancer Discov       Date:  2016-07-15       Impact factor: 39.397

8.  Interleukin 15 receptor alpha rs2228059 A > C polymorphism decreased risk of gastric cardiac adenocarcinoma in a Chinese population.

Authors:  Jun Yin; Chao Liu; Xu Wang; Liming Wang; Yijun Shi; Weifeng Tang; Guowen Ding; Ruiping Liu; Suocheng Chen; Haiyong Gu; Liang Zheng
Journal:  Tumour Biol       Date:  2014-04-03

9.  IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.

Authors:  Daniel A Vallera; Martin Felices; Ron McElmurry; Valarie McCullar; Xianzheng Zhou; Joerg Uwe Schmohl; Bin Zhang; Alexander J Lenvik; Angela Panoskaltsis-Mortari; Michael R Verneris; Jakub Tolar; Sarah Cooley; Daniel J Weisdorf; Bruce R Blazar; Jeffrey S Miller
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531

10.  A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL.

Authors:  Bo-Wei Han; Dan-Dan Feng; Zhi-Gang Li; Xue-Qun Luo; Hua Zhang; Xiao-Juan Li; Xing-Ju Zhang; Ling-Ling Zheng; Cheng-Wu Zeng; Kang-Yu Lin; Peng Zhang; Ling Xu; Yue-Qin Chen
Journal:  Hum Mol Genet       Date:  2011-09-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.